About Instituto de Investigaciones Clinicas Quilmes
"El Instituto de Investigaciones Clínicas Quilmes SRL es una institución abocada exclusivamente a la realización de estudios clínicos ambulatorios, en fase II, III y IV. Con una vasta experiencia del staff en estudios cardiológicos, reumatológicos, oncológicos y en diabetes, tanto en pacientes internados como ambulatorios. Así como entrenamiento y capacitación continua en el área de ensayos clínicos."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Eli Lilly and Company
4
Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)
3
Boehringer Ingelheim
3
Amgen
2
EMD Serono Research & Development Institute, Inc.
2
Gilead Sciences
2
Hoffmann-La Roche
2
R-Pharm International, LLC
2
Arena Pharmaceuticals
1
Celgene
1
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
1
Clinical Trials at Instituto de Investigaciones Clinicas Quilmes
During the past decade, Instituto de Investigaciones Clinicas Quilmes conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 16 clinical trials were completed, i.e. on
average, 84.2% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 11 clinical trials were completed. i.e. 137.5%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
2007-05-01
2010-05-01
Terminated
661
DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
2006-09-01
2009-08-01
Completed
849
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.
2012-01-01
2014-06-01
Completed
2,118
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
2012-08-27
2017-11-21
Completed
481
An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
2013-06-27
2020-11-12
Completed
2,877
Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
2013-07-10
2018-01-18
Completed
6,991
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
2013-10-29
2017-03-22
Terminated
16,784
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas Quilmes" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 3 trials
sponsored, "Boehringer Ingelheim" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "EMD Serono Research & Development Institute, Inc."
with 2 trials sponsored. Other sponsors include 8 different institutions and
companies that sponsored additional 15 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Investigaciones Clinicas Quilmes"
#1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator and "ARTTIC International Management Services" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were
collaborators in the rest 15 trials.
Clinical Trials Conditions at Instituto de Investigaciones Clinicas Quilmes
According to Clinical.Site data, the most researched conditions in "Instituto de Investigaciones Clinicas Quilmes" are
"Rheumatoid Arthritis" (5 trials), "Systemic Lupus Erythematosus" (4 trials), "Pulmonary Arterial Hypertension" (3 trials), "Heart Failure" (2 trials) and "Hypertension" (2 trials). Many other conditions were trialed in "Instituto de Investigaciones Clinicas Quilmes" in a lesser frequency.
Clinical Trials Intervention Types at Instituto de Investigaciones Clinicas Quilmes
Most popular intervention types in "Instituto de Investigaciones Clinicas Quilmes" are "Drug" (24 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (17 trials), "Baricitinib" (3 trials), "Sotatercept" (3 trials), "Darusentan" (2 trials) and "Empagliflozin" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Instituto de Investigaciones Clinicas Quilmes
The vast majority of trials in "Instituto de Investigaciones Clinicas Quilmes" are
26 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Instituto de Investigaciones Clinicas Quilmes
Currently, there are NaN active trials in "Instituto de Investigaciones Clinicas Quilmes".
undefined are not yet recruiting,
4 are recruiting,
2 are Active, not recruiting,
and 1 are Enrolling by invitation.
In total, there were 16 completed trials in Instituto de Investigaciones Clinicas Quilmes,
undefined suspended trials,
and 4 terminated clinical trials to date.
Out of the total trials that were conducted in Instituto de Investigaciones Clinicas Quilmes, 0 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 18 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 1 trials that are defined as “Not Applicable".